
As the first morning of the J.P. Morgan Healthcare Conference dawns, GSK plc is entering the deal-making conversation with a planned acquisition of IDRx, a Plymouth-based biotech working on precision treatments for gastrointestinal stromal tumours.
The British pharma giant said the acquisition includes IDRx’s lead drug candidate, IDRX-42, in development for this rare type of cancer. IDRX-42 is in an ongoing Phase 1/1b trial in patients with advanced GIST.
WATCH ANYTIME FOR FREE
![]() |
Stream NBC10 Boston news for free, 24/7, wherever you are. |
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.
Copyright Boston Business Journal